PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
No Data
No Data available this quarter, please select a different quarter.
2.20
Net debt 2-3x EBITDA - Higher leverage territory. Seth Klarman would scrutinize cash flow stability here. Examine Interest Coverage and Operating Margins carefully.
No Data
No Data available this quarter, please select a different quarter.
3.37
Current ratio above 2.0 - Rock-solid working capital position. Benjamin Graham would approve, but check if excess current assets hurt ROE. Consider examining Cash Conversion Cycle for efficiency.
No Data
No Data available this quarter, please select a different quarter.